Status:
COMPLETED
Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Anesthesia
Neuromuscular Blockade
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The current trial was designed to demonstrate faster recovery in participants undergoing elective surgeries requiring profound neuromuscular blockade induced by rocuronium to a fourth twitch/first twi...
Eligibility Criteria
Inclusion
- Male or female participants
- American Society of Anesthesiologists (ASA) class 1, 2 or 3
- Age \>=18 years
- Scheduled to undergo a surgery requiring profound NMB such as cardiovascular, gynaecologic, neurologic and thoracic surgical procedures under general anesthesia requiring neuromuscular relaxation with rocuronium for endotracheal intubation and if applicable maintenance of NMB in a position allowing neuromuscular monitoring
- Given written informed consent
Exclusion
- Participants known or suspected to have neuromuscular disorders affecting NMB
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00758485
Start Date
October 1 2008
End Date
June 1 2009
Last Update
August 21 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.